James Dunmore lost his two sisters to cystic fibrosis
Made In Chelsea star James Dunmore has told BBC 5 live that he lost two sisters to cystic fibrosis. (Source: BBC News | Health | UK Edition)
Source: BBC News | Health | UK Edition - March 22, 2018 Category: Consumer Health News Source Type: news

Cystic Fibrosis Colorectal Cancer Screening Recommendations Cystic Fibrosis Colorectal Cancer Screening Recommendations
The risk of colorectal cancer is greatly increased in adults with cystic fibrosis. This paper presents CRC screening recommendations for these patients, which differ from those for the general public.Gastroenterology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 22, 2018 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Chantelle Millward on Orkambi drug for cystic fibrosis patients
MPs are debating a petition calling for all people with cystic fibrosis to be given the life-changing, but very expensive, drug. (Source: BBC News | Health | UK Edition)
Source: BBC News | Health | UK Edition - March 19, 2018 Category: Consumer Health News Source Type: news

Student saved by wonder drug NHS won’t pay for
A STUDENT has told how a revolutionary drug that treats cystic fibrosis saved her from a lung transplant. But last night thousands of sufferers of the killer condition were dealt a blow when NHS England announced it would not provide extra funds for the drug Orkambi, which tackles the genetic causes of the disease rather than treating its symptoms. (Source: Daily Express - Health)
Source: Daily Express - Health - March 18, 2018 Category: Consumer Health News Source Type: news

Research Identifies Key Hurdle in Quest for Cystic Fibrosis Treatment
Research offers important insight for new drug therapy to restore proper CFTR folding/function in most with cystic fibrosis, those with the ?F508 mutation. (Source: NIDDK News)
Source: NIDDK News - March 15, 2018 Category: Endocrinology Source Type: news

A Dramatic Improvement in Care for Some People with Cystic Fibrosis
Years of research led to a new medication to overcome the fundamental molecular flaw in some people with cystic fibrosis, greatly reducing their symptoms. (Source: NIDDK News)
Source: NIDDK News - March 15, 2018 Category: Endocrinology Source Type: news

An Important Proof of Principle for the “Combination Therapy” Approach to Treating the Most Common Cystic Fibrosis Mutation
Combination of existing small molecule drug treatment of mutated proteins may lead to new therapies for patients with the most common type of cystic fibrosis. (Source: NIDDK News)
Source: NIDDK News - March 15, 2018 Category: Endocrinology Source Type: news

Improving Genetic Testing for Cystic Fibrosis
Scientists used genetic records of people with cystic fibrosis to find new mutations of the CFTR gene that cause the disease and may improve genetic testing. (Source: NIDDK News)
Source: NIDDK News - March 15, 2018 Category: Endocrinology Source Type: news

East Bay company's stock plummets 81% as drug for cystic fibrosis patients fails
Anthera Pharmaceuticals Inc., which hung its hopes on a two-time loser treatment for cystic fibrosis patients, said the drug failed in a late-stage trial. The stock of the Hayward-based company (NASDAQ: ANTH) fell 81 percent Monday, from $2.64 per share to 50 cents at its close. It had dipped as low as 40 cents. Early data from the 140-patient Phase III study of the drug, called Sollpura, showed that the majority of patients with exocrine pancreati c insufficiency who received the drug saw their… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - March 12, 2018 Category: Biotechnology Authors: Ron Leuty Source Type: news

East Bay company's stock plummets 81% as drug for cystic fibrosis patients fails
Anthera Pharmaceuticals Inc., which hung its hopes on a two-time loser treatment for cystic fibrosis patients, said the drug failed in a late-stage trial. The stock of the Hayward-based company (NASDAQ: ANTH) fell 81 percent Monday, from $2.64 per share to 50 cents at its close. It had dipped as low as 40 cents. Early data from the 140-patient Phase III study of the drug, called Sollpura, showed that the majority of patients with exocrine pancreati c insufficiency who received the drug saw their… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - March 12, 2018 Category: Pharmaceuticals Authors: Ron Leuty Source Type: news

Pig out: How an East Bay drug maker is betting on porcine-less disruption of cystic fibrosis
The company's drug offers promise to cystic fibrosis patients. But does it have enough cash to get it to the FDA finish line? (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - March 7, 2018 Category: American Health Authors: Ron Leuty Source Type: news

Pig out: How an East Bay drug maker is betting on porcine-less disruption of cystic fibrosis
The company's drug offers promise to cystic fibrosis patients. But does it have enough cash to get it to the FDA finish line? (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - March 7, 2018 Category: Biotechnology Authors: Ron Leuty Source Type: news

ICER releases draft report on cystic fibrosis therapies
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - March 1, 2018 Category: Drugs & Pharmacology Source Type: news

‘Holy grail’ of gene therapy still a long way off for cystic fibrosis
Conventional treatments developed by Vertex help many sufferers, but they have a hefty price tag (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - February 28, 2018 Category: Pharmaceuticals Source Type: news

Scholarship Opportunity for All Children’s Nurses to Advance Your Nursing Career (for EDNP/MBA)
Scholarship Opportunity for All Children’s Nurses to Advance Your Nursing Career (for EDNP/MBA) p{ margin:10px 0; padding:0; } table{ border-collapse:collapse; } h1,h2,h3,h4,h5,h6{ display:block; margin:0; padding:0; } img,a img{ border:0; height:auto; outline:none; text-decoration:none; } body,#bodyTable,#bodyCell{ height:100%; margin:0; padding:0; width:100%; } .mcnPreviewText{ display:none !important; } #outlook a{ padding:0; } img{ -ms-interpolation-mode:bicubic; } table{ mso-table-lspace:0pt; mso-table-rspace:0pt; }...
Source: Johns Hopkins University and Health Systems Archive - February 23, 2018 Category: Nursing Source Type: news

Why and when aspergillosis first appears in cystic fibrosis patients?
Thursday, February 15, 2018 - 10:48Slide presentation (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - February 15, 2018 Category: Respiratory Medicine Authors: ROrritt Source Type: news

Vertex says non-opioid pain drug hits mark in study
Vertex Pharmaceuticals has unveiled promising findings from a study of one of its experimental drugs — only this time, the treatment doesn’t target cystic fibrosis. Boston-based Vertex (Nasdaq: VRTX), which largely focuses on the lung disorder, said Wednesday that its non-opioid medicine for pain had performed well in a mid-stage study. Patients who received the drug, called VX-150, following surgery to remove bunions reported significant pain relief compared to those on placebo, according to… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - February 14, 2018 Category: Biotechnology Authors: Max Stendahl Source Type: news

Cystic fibrosis sufferer's first breath with new lungs
Jennifer Jones, 40, had a lung transplant at the Mayo Clinic in Rochester, Minnesota, in October after a battle with cystic fibrosis had reduced her lung function to 10 percent. (Source: the Mail online | Health)
Source: the Mail online | Health - February 13, 2018 Category: Consumer Health News Source Type: news

FDA Approves New Cystic Fibrosis Drug Combo
(MedPage Today) -- Symdeko approved for patients with specific CFTR mutations (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - February 13, 2018 Category: American Health Source Type: news

FDA Clears Tezacaftor/Ivacaftor Combo for Cystic Fibrosis FDA Clears Tezacaftor/Ivacaftor Combo for Cystic Fibrosis
Symdeko is for people aged 12 years and older who have two copies of the F508del mutation in the CFTR gene or who have at least one mutation that is responsive to tezacaftor/ivacaftor.FDA Approvals (Source: Medscape FamilyMedicine Headlines)
Source: Medscape FamilyMedicine Headlines - February 13, 2018 Category: Primary Care Tags: Pulmonary Medicine News Alert Source Type: news

Vertex scores FDA approval for new cystic fibrosis drug
Vertex Pharmaceuticals said Monday that the FDA has approved its third drug for cystic fibrosis, lifting shares of the Boston-based company. Vertex (Nasdaq: VRTX) said the drug — a combination of Kalydeco, which was approved in 2012, and a new medicine called tezacaftor — will be sold under the brand name Symdeko. It will begin shipping to pharmacies in the U.S. this week, and will have a list price of $292,000 per year, the compa ny said. "This approval is an important milestone in our journey… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - February 12, 2018 Category: American Health Authors: Max Stendahl Source Type: news

Vertex scores FDA approval for new cystic fibrosis drug
Vertex Pharmaceuticals said Monday that the FDA has approved its third drug for cystic fibrosis, lifting shares of the Boston-based company. Vertex (Nasdaq: VRTX) said the drug — a combination of Kalydeco, which was approved in 2012, and a new medicine called tezacaftor — will be sold under the brand name Symdeko. It will begin shipping to pharmacies in the U.S. this week, and will have a list price of $292,000 per year, the compa ny said. "This approval is an important milestone in our journey… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - February 12, 2018 Category: Biotechnology Authors: Max Stendahl Source Type: news

FDA Approves Symdeko (tezacaftor/ivacaftor and ivacaftor) to Treat Cystic Fibrosis in People Ages 12 and Older with Certain Mutations in the CFTR Gene
BOSTON--(BUSINESS WIRE) Feb 12, 2018 -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) approved Symdeko (tezacaftor/ivacaftor and ivacaftor) for treating the underlying cause of... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - February 12, 2018 Category: Drugs & Pharmacology Source Type: news

Emerging Therapeutic Strategies for CF-Related Diabetes Emerging Therapeutic Strategies for CF-Related Diabetes
A better understanding of the mechanistic basis of cystic fibrosis-related diabetes has led to the development of exciting new treatment options.Journal of the Endocrine Society (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 12, 2018 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news

From the heart: The tale of a three-time transplant recipient
Playing youth hockey and Little League in the spring of 1988, I started to become easily fatigued. I became very weak and could no longer run around. By May, a visit to my pediatrician resulted in a trip to the Boston Children’s Hospital Cardiology Clinic on Fegan 6 and the first of many cardiac catheterizations I would receive in my life. The results of that first procedure were shared in my corner room across from the nurses’ station on 6 East (the cardiac step-down at the time): I would need a heart transplant for cardiomyopathy. It was Friday the 13th. I was 10 years old. Tim, before he ...
Source: Thrive, Children's Hospital Boston - February 7, 2018 Category: Pediatrics Authors: Tim Gallagher Tags: Our Patients’ Stories cardiac catheterization cardiomyopathy heart transplant Heart transplant program kidney transplant Pediatric Transplant Center (PTC) Source Type: news

Texas woman and Alabama boy both die of flu on Sunday
Heather Holland, 38, of Texas, died on Sunday from the flu after refusing to take Tamiflu. Aaron Masterson, 12, died the same day after battling cystic fibrosis, made deadly by the flu. (Source: the Mail online | Health)
Source: the Mail online | Health - February 6, 2018 Category: Consumer Health News Source Type: news

The 2nd Manchester Cystic Fibrosis Conference: Facing the Challenges of Today
Date: Tuesday, February 6, 2018Year: 2018Location: Stoller Hall - Chetham's School of Music, Hunts Bank, Manchester, M31DAContent-type: current_conferences (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - February 6, 2018 Category: Respiratory Medicine Authors: ROrritt Source Type: news

Vertex picks cystic fibrosis triple combos for Phase III trials
(Reuters) - Vertex Pharmaceuticals said on Wednesday it selected two next-generation cystic fibrosis drugs to advance into late-stage testing of triple-combination therapies that could eventually treat up to 90 percent of patients with the life-shortening lung disease. (Source: Reuters: Health)
Source: Reuters: Health - January 31, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Vertex Picks'Impressive' Cystic Fibrosis Drugs To Aim For A Multibillion-Dollar Market
Vertex Pharmaceuticals has picked two cystic fibrosis drugs to test in combination with its existing CF medicine, Kalydeco, as part of two different three-drug combinations aimed at helping as many as 90% of patients with cystic fibrosis. (Vertex's current offerings can treat half.) (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - January 31, 2018 Category: Pharmaceuticals Authors: Matthew Herper, Forbes Staff Tags: NASDAQ:VRTX Source Type: news

Vertex unveils promising data on new cystic fibrosis drugs as sales top $2B
Vertex Pharmaceuticals Inc. said Wednesday that sales of its two approved cystic fibrosis drugs jumped 29 percent in 2017 to nearly $2.2 billion. And yet those jaw-dropping figures might be eclipsed by another, from ongoing studies of the Boston-based company ’s next generation of treatments. Vertex (Nasdaq: VRTX) reported data from mid-stage trials of two experimental drug cocktails that the company believes could help nearly all patients with the lung disease. According to Vertex, patients in… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - January 31, 2018 Category: Biotechnology Authors: Max Stendahl Source Type: news

Vertex unveils promising data on new cystic fibrosis drugs as sales top $2B
Vertex Pharmaceuticals Inc. said Wednesday that sales of its two approved cystic fibrosis drugs jumped 29 percent in 2017 to nearly $2.2 billion. And yet those jaw-dropping figures might be eclipsed by another, from ongoing studies of the Boston-based company ’s next generation of treatments. Vertex (Nasdaq: VRTX) reported data from mid-stage trials of two experimental drug cocktails that the company believes could help nearly all patients with the lung disease. According to Vertex, patients in… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - January 31, 2018 Category: American Health Authors: Max Stendahl Source Type: news

Corbus Cystic Fibrosis Drug to Get FDA Review on Flare-up Data Corbus Cystic Fibrosis Drug to Get FDA Review on Flare-up Data
Corbus Pharmaceuticals Holdings Inc said on Monday the U.S. Food and Drug Administration will evaluate its experimental cystic fibrosis drug without requiring proof the product improves lung function, dramatically cutting the time and cost it will take Corbus to develop the drug.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 30, 2018 Category: Consumer Health News Tags: Pulmonary Medicine News Source Type: news

Corbus Pharma gets $25M grant, FDA nod for cystic fibrosis drug trial
Norwood-based Corbus Pharmaceuticals said Tuesday that it has received a $25 million grant from a cystic fibrosis research group to help fund an upcoming study of a drug targeting symptoms of the lung disease. Corbus (Nasdaq: CRBP) said that the development award from the Cystic Fibrosis Foundation would allow it to conduct a mid-stage study of its drug, called lenabasum. The nonprofit group also funded an earlier trial of lenabasum. Unlike cystic fibrosis treatments currently sold by Boston-based… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - January 30, 2018 Category: Biotechnology Authors: Max Stendahl Source Type: news

Corbus cystic fibrosis drug to get FDA review on flare-up data
(Reuters) - Corbus Pharmaceuticals Holdings Inc said on Monday the U.S. Food and Drug Administration will evaluate its experimental cystic fibrosis drug without requiring proof the product improves lung function, dramatically cutting the time and cost it will take Corbus to develop the drug. (Source: Reuters: Health)
Source: Reuters: Health - January 29, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

FDA wants more clinical data for Aradigm ’ s inhaled lung drug
Aradigm Corp. (NSDQ:ARDM) shares tumbled today after the company reported that the FDA denied its application for an inhaled drug designed to treat non-cystic fibrosis bronchiectasis patients with chronic lung infections. The agency’s complete response letter reportedly highlighted an array of concerns with the initial application, including product quality and the company’s clinical data. Get the full story at our sister site, Drug Delivery Business News. The post FDA wants more clinical data for Aradigm’s inhaled lung drug appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - January 29, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Food & Drug Administration (FDA) Pharmaceuticals Regulatory/Compliance Respiratory Wall Street Beat Aradigm Corp. Source Type: news

Cystic fibrosis bacterial burden begins during first years of life
(University of North Carolina Health Care) Cystic fibrosis shortens life by making the lungs prone to repeated bacterial infections and inflammation. UNC School of Medicine researchers have now shown for the first time that the lungs' bacterial population changes in the first few years of life as respiratory infections and inflammation set in. This research offers a way to predict the onset of lung disease in children with CF and suggests a larger role for preventive therapies, such as hypertonic saline. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 19, 2018 Category: International Medicine & Public Health Source Type: news

FDA Panel Does Not Recommend Cipro Dispersion for Inhalation FDA Panel Does Not Recommend Cipro Dispersion for Inhalation
An FDA panel did not recommend ciprofloxacin dispersion for inhalation for non-cystic fibrosis bronchiectasis in patients with chronic lung infections with Pseudomonas aeruginosa.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 15, 2018 Category: Consumer Health News Tags: Pulmonary Medicine News Source Type: news

Gene editing – and what it really means to rewrite the code of life
We now have a precise way to correct, replace or even delete faulty DNA.Ian Sample explains the science, the risks and what the future may holdSo what is gene editing?Scientists liken it to the find and replace feature used to correct misspellings in documents written on a computer. Instead of fixing words, gene editing rewrites DNA, the biological code that makes up the instruction manuals of living organisms. With gene editing, researchers can disable target genes,correct harmful mutations, and change the activity of specific genes in plants and animals, including humans.What ’s the point?Much of the excitement aro...
Source: Guardian Unlimited Science - January 15, 2018 Category: Science Authors: Ian Sample Science editor Tags: Genetics Medical research Science Health Biology Source Type: news

Screen for Colorectal Cancer Earlier, More Often in People With Cystic Fibrosis Screen for Colorectal Cancer Earlier, More Often in People With Cystic Fibrosis
Adults with cystic fibrosis (CF) should undergo colorectal cancer (CRC) screening with colonoscopy beginning at age 40 and be rescreened every five years, advise consensus recommendations from the Cystic Fibrosis Foundation.Reuters Health Information (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - January 12, 2018 Category: Radiology Tags: Pulmonary Medicine News Source Type: news

James Bliska to Lead Dartmouth Cystic Fibrosis Research Cluster
Noted molecular biologist James Bliska, PhD, is joining the Geisel School of Medicine at Dartmouth as a Distinguished Professor in Microbiology and Immunology and senior lead faculty member of the Personalized Treatments for Cystic Fibrosis (CF) Cluster, a cross-Dartmouth group of investigators established to develop innovative, personalized medicine and treatments for CF and lung infections caused by opportunistic pathogens. (Source: News at Dartmouth Medical School)
Source: News at Dartmouth Medical School - January 8, 2018 Category: Hospital Management Authors: Timothy Dean Tags: News Press Release Research academic cluster cystic fibrosis faculty Home-feature Source Type: news

Vertex’s cystic fibrosis treatment makes it a hot company
Biotech group’s promising results help it defy broader investor fears over sector (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - January 8, 2018 Category: Pharmaceuticals Source Type: news

Cystic fibrosis treatment: How can you put a price on my little girl’s life?
WHEN the alarm goes at 5.30am every day I have to fight the instinct to hide under the duvet like a child and avoid starting the mammoth treatment regime that lies ahead for our five-year-old daughter Charlotte. (Source: Daily Express - Health)
Source: Daily Express - Health - January 2, 2018 Category: Consumer Health News Source Type: news

Screening for CRC cost  effective in patients with cystic fibrosis
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - January 1, 2018 Category: Drugs & Pharmacology Source Type: news

Bone Deficits Seen at Distal Tibia in Adults With Cystic Fibrosis Bone Deficits Seen at Distal Tibia in Adults With Cystic Fibrosis
Adult patients with cystic fibrosis (CF) have decreased volumetric bone mineral density (vBMD) and stiffness in the distal tibia, compared with healthy individuals, according to new research.Reuters Health Information (Source: Medscape Orthopaedics Headlines)
Source: Medscape Orthopaedics Headlines - December 27, 2017 Category: Orthopaedics Tags: Diabetes & Endocrinology News Source Type: news

This baby was born from an embryo frozen 24 years ago
When Tina Gibson got married seven years ago, she knew it was unlikely that she would have children naturally. Her husband, 33-year-old Benjamin Gibson, had cystic fibrosis, a condition that can make men infertile, the couple told CNN. The East Tennessee couple decided they would eventually adopt a child instead — and that they would foster several children […]Related:FDA approves first gene therapy for an inherited diseaseThis model lost a leg because of an infection from tampons. Here’s what she wants you to know.Debate erupts within HHS about ‘words to avoid’ such as ‘...
Source: Washington Post: To Your Health - December 20, 2017 Category: Consumer Health News Source Type: news

She finally had a baby naturally — with a 24-year-old frozen embryo.
When Tina Gibson got married seven years ago, she knew it was unlikely that she would have children naturally. Her husband, 33-year-old Benjamin Gibson, had cystic fibrosis, a condition that can make men infertile, the couple told CNN. The East Tennessee couple decided they would eventually adopt a child instead — and that they would foster several children […]Related:FDA approves first gene therapy for an inherited diseaseThis model lost a leg because of an infection from tampons. Here’s what she wants you to know.Debate erupts within HHS about ‘words to avoid’ such as ‘...
Source: Washington Post: To Your Health - December 20, 2017 Category: Consumer Health News Source Type: news

New 'checkpoint' model that could identify potential drugs to treat genetic disorders
(University of Bradford) A new 'checkpoint' model which can be used to identify potential treatments for genetic disorders such as cystic fibrosis and Duchenne muscular dystrophy (DMD) has been proposed by a team of Bradford scientists. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 18, 2017 Category: International Medicine & Public Health Source Type: news

What is DIOS?
Discussion Cystic fibrosis (CF) is an autosomal recessive disorder caused by mutations in the cystic fibrosis transmembrane receptor (CFTR). It is found in the epithelium of the bronchi, intestine, pancreatic duct and biliary tree. It regulates chloride, bicarbonate and water secretion. The heterozygous state helps prevent against secretory diarrhea, but the homozygous state causes thickened secretions in the hollow tubes of the lungs and digestive tract. There are multiple mutations (> 2000) which have been currently classified into classes depending on their protein production and activity. CF patients generally are l...
Source: PediatricEducation.org - December 18, 2017 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news

Stunning gene therapy breakthrough driven by great dedication and graft | Robin McKie
We need more than ever to celebrate advances in medical science – though they may take years to emergeThere has been a surprising outbreak of the use of the c-word among medical researchers over the past few days. Normally cautious in their language, they have nevertheless been wielding the term “cure” when discussing the long-term potential of two separate treatments for inherited ailments that were announced last week. Such enthusiasm is striking.In one case, scientists based at St Bartholomew ’s, London – who have been working on the inherited bleeding disorder haemophilia A –outlined...
Source: Guardian Unlimited Science - December 17, 2017 Category: Science Authors: Robin McKie Tags: Medical research Science Genetics Biology Cystic fibrosis Society Huntington's disease Alzheimer's Dementia Source Type: news